MEP39308A - Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method - Google Patents

Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Info

Publication number
MEP39308A
MEP39308A MEP-393/08A MEP39308A MEP39308A ME P39308 A MEP39308 A ME P39308A ME P39308 A MEP39308 A ME P39308A ME P39308 A MEP39308 A ME P39308A
Authority
ME
Montenegro
Prior art keywords
substance
subcutaneous dose
fsh
substances
amount equivalent
Prior art date
Application number
MEP-393/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Evert Johannes Bunschoten
Bennink Herman Jan Tijmen Coelingh
Original Assignee
Ares Trading S A Chateau De Vaumarcus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S A Chateau De Vaumarcus filed Critical Ares Trading S A Chateau De Vaumarcus
Publication of MEP39308A publication Critical patent/MEP39308A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-393/08A 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method MEP39308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077221 2002-06-07
PCT/NL2003/000370 WO2003103770A2 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Publications (1)

Publication Number Publication Date
MEP39308A true MEP39308A (en) 2011-02-10

Family

ID=29724462

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-393/08A MEP39308A (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Country Status (21)

Country Link
US (1) US7815912B2 (no)
EP (1) EP1511537B1 (no)
JP (1) JP2005530818A (no)
KR (1) KR20050058285A (no)
CN (1) CN1684737A (no)
AU (1) AU2003274929B2 (no)
BR (1) BR0305033A (no)
CA (1) CA2488719A1 (no)
EA (1) EA009371B1 (no)
ES (1) ES2399962T3 (no)
IL (1) IL165522A0 (no)
IS (1) IS7586A (no)
ME (1) MEP39308A (no)
MX (1) MXPA04012246A (no)
NO (1) NO20045304L (no)
NZ (1) NZ536984A (no)
PL (1) PL373991A1 (no)
RS (1) RS105004A (no)
UA (1) UA81251C2 (no)
WO (1) WO2003103770A2 (no)
ZA (1) ZA200409857B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236785B2 (en) * 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
EP2734239A2 (en) 2011-07-18 2014-05-28 Arts Biologics A/S Long acting luteinizing hormone (lh) compound
US9282995B2 (en) * 2011-12-22 2016-03-15 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
US9216037B2 (en) 2013-06-21 2015-12-22 Previvo Genetics, Llc Uterine lavage for embryo retrieval
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
MA52548A (fr) 2016-07-21 2021-05-26 ObsEva SA Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches
AU2020340670A1 (en) 2019-09-03 2022-04-07 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh) 2020-02-10 2022-11-22 奥布赛瓦股份公司 用于催产素受体拮抗剂疗法的生物标志物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0788799A3 (en) 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
CN1199642A (zh) * 1997-05-16 1998-11-25 Asta药物股份公司 治疗不育症的lhrh-拮抗剂
DE69831241T2 (de) * 1997-06-20 2006-03-23 Akzo Nobel N.V. Gonadotropin freisetzendes Hormon Antagonist
JP2002512975A (ja) * 1998-04-23 2002-05-08 アスタ メディカ アクチエンゲゼルシャフト 受精能力障害の治療薬
ES2258445T3 (es) * 1999-02-24 2006-09-01 Novo Nordisk A/S Metodo in vitro para la sincronizacion de la maduracion de ovocitos.
EP1140132A1 (en) 1999-06-23 2001-10-10 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
US20030092628A1 (en) * 1999-06-23 2003-05-15 De Greef Henrik Johan Matthieu Maria Gonadotropin releasing hormone antagonist
MXPA04002125A (es) * 2001-09-12 2004-07-08 Applied Research Systems Uso de la hl en la hiperestimulacion ovarica controlada.
WO2003055524A1 (en) 2001-12-21 2003-07-10 Pantarhei Bioscience B.V. Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Also Published As

Publication number Publication date
ZA200409857B (en) 2006-02-22
EA009371B1 (ru) 2007-12-28
ES2399962T3 (es) 2013-04-04
AU2003274929A1 (en) 2003-12-22
CN1684737A (zh) 2005-10-19
US7815912B2 (en) 2010-10-19
MXPA04012246A (es) 2005-04-08
UA81251C2 (en) 2007-12-25
CA2488719A1 (en) 2003-12-18
AU2003274929B2 (en) 2008-04-10
EP1511537B1 (en) 2012-11-21
NO20045304L (no) 2005-02-07
PL373991A1 (en) 2005-09-19
IS7586A (is) 2004-12-03
WO2003103770A2 (en) 2003-12-18
KR20050058285A (ko) 2005-06-16
BR0305033A (pt) 2004-11-09
NZ536984A (en) 2008-01-31
EA200401619A1 (ru) 2005-06-30
US20050235374A1 (en) 2005-10-20
WO2003103770A3 (en) 2004-04-22
RS105004A (en) 2007-02-05
JP2005530818A (ja) 2005-10-13
EP1511537A2 (en) 2005-03-09
IL165522A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
Schneider et al. Estradiol and the neuroendocrine control of LH release in vitro
ITMI941048A1 (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
AR011217A1 (es) UN PÉPTIDO ANTAGONISTA DE GNRH, UNA COMPOSICIoN FARMACÉUTICA PARA INHIBIR LA SECRECIoN DE GONADOTROPINAS EN MAMíFEROS Y UN COMPUESTO INTERMEDIARIO PARA PREPARAR UN PÉPTIDO ANTAGONISTA DE GNRH.
Huirne et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study
ROSEMBERG et al. Clinical effect of human urinary postmenopausal gonadotropin
MEP39308A (en) Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
RU2005136527A (ru) Унитарная комбинация fsh и hcg
KR950703359A (ko) 임신치료를 위한 파라소면(parathormone), 그 생물학적 활성 프래그먼트(fragment) 및 관련 펩티드(peptide)의 용도
Gerris et al. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 μg), GnRH agonist (buserelin, 500 μg) and human chorionic gonadotrophin (10 000 IU)
Reichman et al. GnRH antagonist-based protocols for in vitro fertilization
Tur-Kaspa et al. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
WO2005018657A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
AU2002358346A1 (en) Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
BRPI0409571A (pt) métodos e kits para a manutenção de gravidez, tratamento de cistos foliculares, e sincronização da ovulação empregando-se hormÈnio de luteinização
WO2005019457A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
AU5814990A (en) A process for treating infertility and an agent for use in the process
Mills et al. Is the postovulatory release of follicle-stimulating hormone in the rabbit mediated by luteinizing hormone-releasing hormone?
MXPA03009447A (es) Inhibidor de aromatasa de dosis unica para tratamiento de infertilidad.
KR20030051828A (ko) 에스트로겐 의존성 질환의 병용 치료법
Malven et al. A mechanism antagonizing the luteotrophic action of exogenous prolactin in rats
Curry Alterations in incidence of mating and copulation-induced ovulation after olfactory bulb ablation in female rats
BR9611760A (pt) Novos antagonistas lh-rh com efeito aperfeiçoado
Bretzlaff Physiology and pharmacology of the postpartum cow and retained fetal membranes
Tarhan et al. Oxytocin-induced contractions of the rabbit corpus cavernosum